Yüklüyor......

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

In the absence of treatment, overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in breast cancer. In the last decade, monoclonal antibodies and small molecule tyrosine kinase inhibitors have significantly improved the outcome of HER2-positive breast cance...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Geuna, Elena, Montemurro, Filippo, Aglietta, Massimo, Valabrega, Giorgio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2012
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846413/
https://ncbi.nlm.nih.gov/pubmed/24367201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S25868
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!